Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age

Trial Profile

A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs JNJ 64400141 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors Janssen Vaccines and Prevention B.V
  • Most Recent Events

    • 22 Jan 2019 Planned initiation date changed from 7 Jan 2019 to 14 Jan 2019.
    • 27 Dec 2018 Planned initiation date changed from 15 Dec 2018 to 7 Jan 2019.
    • 09 Oct 2018 Planned End Date changed from 3 May 2021 to 30 May 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top